戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  usual absence of rheumatoid factor and anti-cyclic citrullinated peptide.
2 autoantibodies (rheumatoid factor [RF], anti-cyclic citrullinated peptide 2 [anti-CCP-2], and RF isot
3 llinated alpha-enolase peptide 1 (CEP-1) and cyclic citrullinated peptide 2 were measured by enzyme-l
4 reduced titers of rheumatoid factor and anti-cyclic citrullinated peptide Abs are recorded, the mecha
5 tivity Score 28, rheumatic factor [RF], anti-cyclic citrullinated peptide [aCCP], medications) were e
6 factor STAT3, of antibodies directed against cyclic citrullinated peptides and Bhsp65, and of the act
7  IgA, and IgG rheumatoid factors (RFs), anti-cyclic citrullinated peptide, and antimicrobial antibodi
8 nts were HLA-DRB1 typed, and tested for anti-cyclic citrullinated peptide (anti-CCP) and rheumatoid f
9  two biomarkers related to the disease, anti-cyclic citrullinated peptide (anti-CCP) and rheumatoid f
10                The sera were tested for anti-cyclic citrullinated peptide (anti-CCP) antibodies and a
11   In patients with RA, higher levels of anti-cyclic citrullinated peptide (anti-CCP) antibodies and c
12     In addition to measurement of serum anti-cyclic citrullinated peptide (anti-CCP) antibodies and H
13                                         Anti-cyclic citrullinated peptide (anti-CCP) antibodies are a
14  and had significantly higher titers of anti-cyclic citrullinated peptide (anti-CCP) antibodies compa
15                                         Anti-cyclic citrullinated peptide (anti-CCP) antibodies have
16 actor (IgM-RF), IgG-RF, IgA-RF, and IgG anti-cyclic citrullinated peptide (anti-CCP) antibodies toget
17 ed for rheumatoid factor (RF) isotypes, anti-cyclic citrullinated peptide (anti-CCP) antibodies, 14 c
18 sensitivity C-reactive protein (hsCRP), anti-cyclic citrullinated peptide (anti-CCP) antibodies, inte
19 ent subsets, defined according to their anti-cyclic citrullinated peptide (anti-CCP) antibody status,
20 int examination, rheumatoid factor, and anti-cyclic citrullinated peptide (anti-CCP) antibody testing
21 e impact of disease activity, sex, age, anti-cyclic citrullinated peptide (anti-CCP) antibody titer,
22 or the presence of anti-PAD-4 antibody, anti-cyclic citrullinated peptide (anti-CCP) antibody, and rh
23                                     The anti-cyclic citrullinated peptide (anti-CCP) enzyme-linked im
24 e interactions between SE, smoking, and anti-cyclic citrullinated peptide (anti-CCP) status, adjusted
25              Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) were also assaye
26 heumatoid factors (RF), and of antibodies to cyclic citrullinated peptide (anti-CCP) were assayed.
27            Second-generation assays for anti-cyclic citrullinated peptide (anti-CCP), a highly sensit
28                         Serum levels of anti-cyclic citrullinated peptide (anti-CCP), anti-citrullina
29 ere tested for the presence of antibodies to cyclic citrullinated peptide (anti-CCP), rheumatoid fact
30 ies that investigated second-generation anti-cyclic citrullinated peptide antibodies (anti-CCP2) in p
31 mmatory arthritis but were positive for anti-cyclic citrullinated peptide antibodies and/or >/=2 rheu
32 munoglobulin G, antinuclear antibodies, anti-cyclic citrullinated peptide antibodies, rheumatoid fact
33 m measurements of rheumatoid factor and anti-cyclic citrullinated peptide antibodies, second-generati
34 in antibody (ACPA; by second-generation anti-cyclic citrullinated peptide antibody enzyme-linked immu
35 nalysis Workshop 16 for associated with Anti-cyclic citrullinated peptide antibody further demonstrat
36 unoglobulin G, antinuclear antibody, or anti-cyclic citrullinated peptide antibody levels were found.
37 variable model, adjusting for age, sex, anti-cyclic citrullinated peptide antibody positivity, and th
38 luding a positive rheumatoid factor, or anti-cyclic citrullinated peptide antibody result, or both.
39                                         Anti-cyclic citrullinated peptide antibody testing is used to
40 RA in 3 independent seropositive (RF or anti-cyclic citrullinated peptide antibody) RA cohorts but no
41  factor (RF; including isotypes) and/or anti-cyclic citrullinated peptide antibody.
42 atoid arthritis (RA), especially more severe cyclic-citrullinated peptide antibody-positive (anti-CCP
43 ve correlation between FHR3 mRNA level, anti-cyclic citrullinated peptide (CCP) antibodies and rheuma
44 ients with RA who were positive for the anti-cyclic citrullinated peptide (CCP) antibodies were more
45 atoid factor (RF) and autoantibodies against cyclic citrullinated peptide (CCP) are markers that migh
46  RA patients, as determined by reactivity to cyclic citrullinated peptide (CCP).
47 were seropositive for autoantibodies against cyclic citrullinated peptide (CCP).
48 ociated with RA (P<10(-4)): *0301 with anti- cyclic citrullinated peptide-negative RA and *0701 indep
49              Antibodies against both CII and cyclic citrullinated peptide, one such citrullinated ant
50  No association with rheumatoid factor, anti-cyclic citrullinated peptide, or the Disease Activity Sc
51 odies that can recognize immunoglobulins and cyclic citrullinated peptides, suggesting early defects
52 city (71% vs. 63%; P = 0.045), elevated anti-cyclic citrullinated peptide titer (122 vs. 201; P = 0.0